Stay updated on Clinical Trial: PF-05280014 vs. Trastuzumab/Taxotere+Carboplatin

Sign up to get notified when there's something new on the Clinical Trial: PF-05280014 vs. Trastuzumab/Taxotere+Carboplatin page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: PF-05280014 vs. Trastuzumab/Taxotere+Carboplatin page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:31:55.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the percentage of patients with steady state Cycle 5 Ctrough of trastuzumab-Pfizer compared to EU-approved trastuzumab in the neoadjuvant treatment of patients with operable HER2-positive breast cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:46.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as histologically confirmed HER2 overexpressing invasive breast cancer and plans for definitive surgical resection. Previously, this section indicated that no information was provided.
    Difference
    9%
    Check dated 2024-05-22T21:32:46.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:48:27.000Z thumbnail image

Stay in the know with updates to Clinical Trial: PF-05280014 vs. Trastuzumab/Taxotere+Carboplatin

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: PF-05280014 vs. Trastuzumab/Taxotere+Carboplatin page.